Month 24 Outcomes After Treatment Initiation With Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial

IMPORTANCE: Two-year outcomes are reported comparing eyes originally assigned to aflibercept or bevacizumab to assess the need for continued anti–vascular endothelial growth factor (VEGF) therapy for macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) from...

Full description

Saved in:
Bibliographic Details
Published in:JAMA Ophthalmol
Main Authors: Scott, Ingrid U., Oden, Neal L., VanVeldhuisen, Paul C., Ip, Michael S., Blodi, Barbara A., Chan, Clement K.
Format: Artigo
Language:Inglês
Published: American Medical Association 2019
Subjects:
Original Investigation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6802250/
https://ncbi.nlm.nih.gov/pubmed/31600368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2019.3947
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items